Get the Stockscreener App
87.55
0.22%
-0.19
After Hours:
87.80
0.25
+0.29%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cvs Health Corp stock is traded at $87.55, with a volume of 8.95M.
It is down -0.22% in the last 24 hours and down -7.51% over the past month.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
See More
Previous Close:
$87.74
Open:
$89.2
24h Volume:
8.95M
Relative Volume:
0.92
Market Cap:
$111.97B
Revenue:
$407.94B
Net Income/Loss:
$2.90B
P/E Ratio:
38.45
EPS:
2.2771
Net Cash Flow:
$7.39B
1W Performance:
+1.30%
1M Performance:
-7.51%
6M Performance:
+12.11%
1Y Performance:
+11.61%
1-Day Range:
$86.12
$89.89
1-Week Range:
$85.80
$89.93
52-Week Range:
$69.51
$110.68
Cvs Health Corp Stock (CVS) Company Profile
Name
Cvs Health Corp
Sector
Industry
Phone
(401) 765-1500
Address
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, ELV, CI, HUM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
87.55 | 111.97B | 407.94B | 2.90B | 7.39B | 2.2771 |
UNH
Unitedhealth Group Inc
|
377.76 | 339.08B | 450.13B | 14.91B | 23.62B | 15.55 |
ELV
Elevance Health Inc
|
425.27 | 92.23B | 201.11B | 4.95B | 6.29B | 22.50 |
CI
Cigna Group
|
282.53 | 74.66B | 278.13B | 6.74B | 7.66B | 23.60 |
HUM
Humana Inc
|
420.38 | 50.48B | 137.20B | 1.15B | 1.27B | 9.3439 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Oct-14-25 | Initiated | Goldman | Buy |
| Aug-18-25 | Upgrade | UBS | Neutral → Buy |
| Aug-14-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-13-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-12-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-30-25 | Upgrade | Edward Jones | Hold → Buy |
| Dec-03-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-18-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-04-24 | Upgrade | TD Cowen | Hold → Buy |
| May-30-24 | Initiated | Robert W. Baird | Neutral |
| May-07-24 | Downgrade | TD Cowen | Buy → Hold |
| May-02-24 | Downgrade | UBS | Buy → Neutral |
| May-01-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-01-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Dec-22-23 | Initiated | HSBC Securities | Buy |
| Sep-19-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-12-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-18-23 | Downgrade | Edward Jones | Buy → Hold |
| May-26-23 | Initiated | Piper Sandler | Overweight |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Resumed | Morgan Stanley | Overweight |
| Jun-17-22 | Initiated | Loop Capital | Buy |
| May-27-22 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-29-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-14-21 | Initiated | Goldman | Buy |
| Dec-01-21 | Initiated | Seaport Research Partners | Buy |
| May-19-21 | Initiated | Wells Fargo | Equal Weight |
| Mar-17-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-08-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-17-20 | Initiated | Piper Sandler | Overweight |
| Jul-01-20 | Initiated | SVB Leerink | Mkt Perform |
| May-14-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-27-19 | Resumed | RBC Capital Mkts | Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Buy |
| Jun-05-19 | Upgrade | Standpoint Research | Hold → Buy |
| Apr-29-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Apr-15-19 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-10-19 | Reiterated | BofA/Merrill | Buy |
| Mar-13-19 | Initiated | Bernstein | Outperform |
| Feb-20-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-18-18 | Initiated | Barclays | Overweight |
| Nov-29-18 | Resumed | Goldman | Neutral |
| Nov-28-18 | Initiated | Evercore ISI | Outperform |
| Oct-26-18 | Resumed | Wolfe Research | Peer Perform |
| Jul-09-18 | Upgrade | Citigroup | Neutral → Buy |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-13-18 | Reiterated | Citigroup | Neutral |
View All
Cvs Health Corp Stock (CVS) Latest News
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
Douglas Lane & Associates LLC Reduces Holdings in CVS Health Corporation $CVS - MarketBeat
Beyond Halloween night: New ways to celebrate the season - CVS Health
CVS Health (CVS) vs Cigna (CI): Which is a Better Stock to Buy? - Yahoo Finance
Humana surges after topping 2027 Medicare star ratings - Reuters
CVS Stock: TD Cowen Warns Of Bottom-Line Pressure For CVS Health Amid Star Ratings Setback - Yahoo Finance
CVS Health Corporation $CVS Shares Purchased by Artemis Investment Management LLP - MarketBeat
Aetna 2027 Star ratings reflect strong clinical quality and member experience - CVS Health
233,794 CVS Health Corporation $CVS Shares Acquired by Hamlin Capital Management LLC - MarketBeat
CVS Health Trades at a Discount to Industry: How to Play the Stock? - Zacks Investment Research
CVS Health Trades at a Discount to Industry: How to Play the Stock? - Yahoo Finance Australia
CVS Caremark: Why transparency matters in pharmacy benefits - CVS Health
Here's Why CVS Health (CVS) is a Strong Growth Stock - Zacks Investment Research
What Does CVS Health (CVS) Gain From Extending Its Drug Distribution Deals To 2032? - Yahoo Finance
CVS Health (CVS) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
CVS Pharmacy® celebrates opening of first pharmacy-focused location in Boston area - CVS Health
CVS will open nearly 20 pharmacies focused on prescriptions and pharmacist care in 2026. - Stock Titan
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now? - Zacks Investment Research
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now? - Yahoo Finance UK
CVS' Health Care Benefits Arm Shows Better Core Trends: What's Ahead? - Yahoo Finance
CVS Health Corporation (NYSE:CVS) Stock Has Average Target Price of $107.24 - MarketBeat
CVS Health Corporation $CVS Stock Acquired by Argent Capital Management LLC - MarketBeat
Fall into wellness: Preventive health tips for older adults, a Q&A with Jean Reidy - CVS Health
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Why Is CVS Health (NYSE:CVS) Drawing NYSE Composite Attention? - Kalkine Media
CVS Health Corporation (CVS) - Yahoo! Finance Canada
CVS Health to hold third quarter 2026 earnings conference call - marketscreener.com
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names - Zacks Investment Research
CVS Health Corporation (CVS) options chain - Yahoo Finance Australia
CVS Health Corporation $CVS Shares Sold by CX Institutional - MarketBeat
MinuteClinic is helping connect more Americans to care - CVS Health
Settling into college: Five ways students can take charge of their health - CVS Health
Cardinal Health, McKesson Extend CVS Distribution Deals to 2032 - Pharmaceutical Commerce
Why Is Cardinal Health and McKesson Stock Trading Higher TodayCVS Health (NYSE:CVS), McKesson (NYSE:MC - Benzinga
CVS Health Corporation (NYSE:CVS) Declares Quarterly Dividend of $0.67 - MarketBeat
McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health - Business Wire
Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health - Yahoo Finance
CVS Health declares quarterly dividend - PR Newswire
DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace? - Zacks Investment Research
Non-operating income (total) of CVS Health Corporation – HAN:CVS - TradingView
CVS Health helps expand school-based food access for Rhode Island students - CVS Health
Hunger Action Month: Supporting healthier communities through better access to nutritious food - CVS Health
MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option - finance.yahoo.com
CVS Health Corporation (CVS) stock price, news, quote and history - Yahoo Finance UK
CVS Health Corporation (CVS) - Yahoo! Finance Canada
CVS Health (CVS) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Ask a CVS Pharmacist: Your top flu shot questions, answered - CVS Health
CVS Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CVS Health CorporationCVS - Business Wire
CVS Health Is Making a Difference in Local Communities, One Classroom at a Time - Yahoo Finance
Cvs Health Corp Stock (CVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvs Health Corp Stock (CVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROBBINS LARRY | Director |
May 21 '26 |
Sale |
93.45 |
370,462 |
34,619,007 |
4,824,799 |
| FARAH ROGER N | Director |
May 21 '26 |
Proposed Sale |
93.68 |
2,817 |
263,886 |
0 |
| ROBBINS LARRY | Director |
May 20 '26 |
Sale |
93.82 |
1,018,000 |
95,510,822 |
5,195,261 |
| ROBBINS LARRY | Director |
May 19 '26 |
Sale |
94.45 |
1,983,538 |
187,341,308 |
6,213,261 |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer |
May 08 '26 |
Sale |
89.58 |
69,551 |
6,230,379 |
10,133 |
| TILAK MANDADI | Officer |
May 08 '26 |
Proposed Sale |
89.58 |
69,551 |
6,230,719 |
0 |
0.75%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):